Table 1.
Baseline patient characteristics
| Baseline Characteristic | Entire Cohort (n=269) |
|---|---|
| Age, yr, mean (SD) | 51.8 (15.4) |
| Male, n (%) | 170 (63.2) |
| Race or ethnicity, n (%) | |
| Aboriginal | 13 (4.8) |
| Asian | 25 (9.3) |
| Black | 25 (9.3) |
| Indian subcontinent | 16 (5.9) |
| Other including multiethnic/preference not to report | 23 (8.6) |
| White | 167 (62.1) |
| Donor source, n (%) | |
| Deceased | 191 (71) |
| Living | 78 (29) |
| Duration of allograft survival before transplant failed | |
| Median (IQR), yr | 10.8 (4.9–16.1) |
| Transplant duration, n (%) | |
| <1 yr | 15 (5.6) |
| >1 yr | 254 (94.4) |
| Transplant year, n (%) | |
| Before 1990 | 16 (5.9) |
| 1990–2000 | 92 (34.2) |
| 2001–2010 | 126 (46.8) |
| 2011–2016 | 35 (13) |
| Primary cause of allograft failure, n (%) | |
| Interstitial fibrosis and tubular atrophy (chronic allograft nephropathy) | 73 (27.1) |
| Other | 51 (19) |
| Chronic antibody-mediated rejection/transplant glomerulopathy | 49 (18.2) |
| Recurrent GN | 24 (8.9) |
| Acute T cell–mediated rejection | 23 (8.6) |
| Unknown | 16 (5.9) |
| Primary nonfunction | 8 (3.0) |
| Acute antibody-mediated rejection | 7 (2.6) |
| Polyomavirus nephropathy | 6 (2.2) |
| Calcineurin inhibitor toxicity | 4 (1.5) |
| Arterial or venous thrombosis | 3 (1.1) |
| De novo GN | 3 (1.1) |
| Obstruction | 2 (0.7) |
| Current immunosuppressive medications, n (%)a | |
| Prednisone | 233 (86.6) |
| Tacrolimus | 142 (52.8) |
| Mycophenolate mofetil | 76 (28.3) |
| Cyclosporine | 53 (19.7) |
| Mycophenolate sodium | 31 (11.5) |
| Azathioprine | 27 (10) |
| Sirolimus | 12 (4.5) |
| Other | 3 (1.11) |
| Treatment for acute rejection any time before to allograft failure, n (%) | |
| Yes | 116 (43.1) |
| No | 109 (40.5) |
| Unknown | 44 (16.4) |
| Comorbid conditions, n (%) | |
| Cancer | 58 (21.6) |
| Cardiovascular disease | 72 (26.8) |
| Diabetes mellitus | 87 (32.3) |
| Smoking, n (%) | |
| Current | 39 (14.5) |
| Former | 83 (30.9) |
| Never | 147 (54.6) |
| Cause of ESKD, n (%) | |
| Other | 95 (35.3) |
| GN | 81 (30.1) |
| Diabetes mellitus | 38 (14.1) |
| Polycystic kidney disease | 24 (8.9) |
| Unknown | 18 (6.7) |
| Hypertension | 13 (4.8) |
| Laboratory parameters, mean (SD) | |
| Hemoglobin, g/L | 95.8 (16.9) |
| Parathyroid hormone, pmol/L | 65.5 (97.5) |
| Serum albumin, g/L | 33.6 (5.7) |
| Calcium (total uncorrected), mmol/L | 2.2 (0.2) |
| Phosphorus, mmol/L | 1.6 (0.6) |
a
Proportions may total >100% as multiple selections were accepted for this field.